Neutrophilia and mortality in women with uterine carcinosarcoma

Rebecca Arend, Anne Van Arsdale, Anar Gojayev, Brandon Michael Roane, David Doo, Charles Leath, Gary L. Goldberg, Gloria Huang

Research output: Contribution to journalArticle

Abstract

Objective: The objective of this study was to investigate the relationship between pre-treatment absolute neutrophil count and clinical outcomes in patients with uterine carcinosarcoma. Methods: In an Institutional Review Board approved, retrospective cohort study of 103 patients with uterine carcinosarcoma, the pre-treatment absolute neutrophil count data were obtained from the medical records, along with clinical, pathologic, treatment, and outcome data. Kaplan-Meier survival estimates were calculated and compared by the log rank test. Univariable and multivariable Cox proportional hazard regression models were used to examine the relationship of pre-treatment absolute neutrophil count with progression-free survival and overall survival. Results: Uterine carcinosarcoma patients in the highest quartile of pre-treatment absolute neutrophil count had significantly reduced progression-free survival (p<0.001, log rank test), and overall survival (p<0.001, log rank test), compared with patients in the lower absolute neutrophil count quartiles. On multivariable analysis, high absolute neutrophil count was an independent poor prognostic factor for disease recurrence, HR 2.97 (95% CI 1.35 to 6.53, p=0.007) for highest versus lowest quartile absolute neutrophil count, and for mortality, HR 4.43 (95% CI 1.64 to 12.00, p= 0.003). Conclusions: High pre-treatment absolute neutrophil count is an independent poor prognostic factor in patients with uterine carcinosarcoma and may be useful as a potential biomarker in clinical trials. The mechanistic relationship of neutrophilia and uterine carcinosarcoma progression merits further investigation.

Original languageEnglish (US)
Pages (from-to)1258-1263
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume29
Issue number8
DOIs
StatePublished - Oct 1 2019

Fingerprint

Carcinosarcoma
Neutrophils
Mortality
Disease-Free Survival
Survival
Therapeutics
Research Ethics Committees
Kaplan-Meier Estimate
Proportional Hazards Models
Medical Records
Cohort Studies
Retrospective Studies
Biomarkers
Clinical Trials
Recurrence

Keywords

  • carcinosarcoma
  • preoperative care
  • uterine cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Neutrophilia and mortality in women with uterine carcinosarcoma. / Arend, Rebecca; Van Arsdale, Anne; Gojayev, Anar; Roane, Brandon Michael; Doo, David; Leath, Charles; Goldberg, Gary L.; Huang, Gloria.

In: International Journal of Gynecological Cancer, Vol. 29, No. 8, 01.10.2019, p. 1258-1263.

Research output: Contribution to journalArticle

Arend, R, Van Arsdale, A, Gojayev, A, Roane, BM, Doo, D, Leath, C, Goldberg, GL & Huang, G 2019, 'Neutrophilia and mortality in women with uterine carcinosarcoma', International Journal of Gynecological Cancer, vol. 29, no. 8, pp. 1258-1263. https://doi.org/10.1136/ijgc-2019-000440
Arend, Rebecca ; Van Arsdale, Anne ; Gojayev, Anar ; Roane, Brandon Michael ; Doo, David ; Leath, Charles ; Goldberg, Gary L. ; Huang, Gloria. / Neutrophilia and mortality in women with uterine carcinosarcoma. In: International Journal of Gynecological Cancer. 2019 ; Vol. 29, No. 8. pp. 1258-1263.
@article{a1dcc2895528477e9f5a4d1f82e4629b,
title = "Neutrophilia and mortality in women with uterine carcinosarcoma",
abstract = "Objective: The objective of this study was to investigate the relationship between pre-treatment absolute neutrophil count and clinical outcomes in patients with uterine carcinosarcoma. Methods: In an Institutional Review Board approved, retrospective cohort study of 103 patients with uterine carcinosarcoma, the pre-treatment absolute neutrophil count data were obtained from the medical records, along with clinical, pathologic, treatment, and outcome data. Kaplan-Meier survival estimates were calculated and compared by the log rank test. Univariable and multivariable Cox proportional hazard regression models were used to examine the relationship of pre-treatment absolute neutrophil count with progression-free survival and overall survival. Results: Uterine carcinosarcoma patients in the highest quartile of pre-treatment absolute neutrophil count had significantly reduced progression-free survival (p<0.001, log rank test), and overall survival (p<0.001, log rank test), compared with patients in the lower absolute neutrophil count quartiles. On multivariable analysis, high absolute neutrophil count was an independent poor prognostic factor for disease recurrence, HR 2.97 (95{\%} CI 1.35 to 6.53, p=0.007) for highest versus lowest quartile absolute neutrophil count, and for mortality, HR 4.43 (95{\%} CI 1.64 to 12.00, p= 0.003). Conclusions: High pre-treatment absolute neutrophil count is an independent poor prognostic factor in patients with uterine carcinosarcoma and may be useful as a potential biomarker in clinical trials. The mechanistic relationship of neutrophilia and uterine carcinosarcoma progression merits further investigation.",
keywords = "carcinosarcoma, preoperative care, uterine cancer",
author = "Rebecca Arend and {Van Arsdale}, Anne and Anar Gojayev and Roane, {Brandon Michael} and David Doo and Charles Leath and Goldberg, {Gary L.} and Gloria Huang",
year = "2019",
month = "10",
day = "1",
doi = "10.1136/ijgc-2019-000440",
language = "English (US)",
volume = "29",
pages = "1258--1263",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Neutrophilia and mortality in women with uterine carcinosarcoma

AU - Arend, Rebecca

AU - Van Arsdale, Anne

AU - Gojayev, Anar

AU - Roane, Brandon Michael

AU - Doo, David

AU - Leath, Charles

AU - Goldberg, Gary L.

AU - Huang, Gloria

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Objective: The objective of this study was to investigate the relationship between pre-treatment absolute neutrophil count and clinical outcomes in patients with uterine carcinosarcoma. Methods: In an Institutional Review Board approved, retrospective cohort study of 103 patients with uterine carcinosarcoma, the pre-treatment absolute neutrophil count data were obtained from the medical records, along with clinical, pathologic, treatment, and outcome data. Kaplan-Meier survival estimates were calculated and compared by the log rank test. Univariable and multivariable Cox proportional hazard regression models were used to examine the relationship of pre-treatment absolute neutrophil count with progression-free survival and overall survival. Results: Uterine carcinosarcoma patients in the highest quartile of pre-treatment absolute neutrophil count had significantly reduced progression-free survival (p<0.001, log rank test), and overall survival (p<0.001, log rank test), compared with patients in the lower absolute neutrophil count quartiles. On multivariable analysis, high absolute neutrophil count was an independent poor prognostic factor for disease recurrence, HR 2.97 (95% CI 1.35 to 6.53, p=0.007) for highest versus lowest quartile absolute neutrophil count, and for mortality, HR 4.43 (95% CI 1.64 to 12.00, p= 0.003). Conclusions: High pre-treatment absolute neutrophil count is an independent poor prognostic factor in patients with uterine carcinosarcoma and may be useful as a potential biomarker in clinical trials. The mechanistic relationship of neutrophilia and uterine carcinosarcoma progression merits further investigation.

AB - Objective: The objective of this study was to investigate the relationship between pre-treatment absolute neutrophil count and clinical outcomes in patients with uterine carcinosarcoma. Methods: In an Institutional Review Board approved, retrospective cohort study of 103 patients with uterine carcinosarcoma, the pre-treatment absolute neutrophil count data were obtained from the medical records, along with clinical, pathologic, treatment, and outcome data. Kaplan-Meier survival estimates were calculated and compared by the log rank test. Univariable and multivariable Cox proportional hazard regression models were used to examine the relationship of pre-treatment absolute neutrophil count with progression-free survival and overall survival. Results: Uterine carcinosarcoma patients in the highest quartile of pre-treatment absolute neutrophil count had significantly reduced progression-free survival (p<0.001, log rank test), and overall survival (p<0.001, log rank test), compared with patients in the lower absolute neutrophil count quartiles. On multivariable analysis, high absolute neutrophil count was an independent poor prognostic factor for disease recurrence, HR 2.97 (95% CI 1.35 to 6.53, p=0.007) for highest versus lowest quartile absolute neutrophil count, and for mortality, HR 4.43 (95% CI 1.64 to 12.00, p= 0.003). Conclusions: High pre-treatment absolute neutrophil count is an independent poor prognostic factor in patients with uterine carcinosarcoma and may be useful as a potential biomarker in clinical trials. The mechanistic relationship of neutrophilia and uterine carcinosarcoma progression merits further investigation.

KW - carcinosarcoma

KW - preoperative care

KW - uterine cancer

UR - http://www.scopus.com/inward/record.url?scp=85072746632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072746632&partnerID=8YFLogxK

U2 - 10.1136/ijgc-2019-000440

DO - 10.1136/ijgc-2019-000440

M3 - Article

C2 - 31320488

AN - SCOPUS:85072746632

VL - 29

SP - 1258

EP - 1263

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 8

ER -